Pfizer (PFE) Capital Expenditures (2009 - 2026)

Pfizer has disclosed Capital Expenditures across 18 years of filings, most recently posting $436.0 million for Q1 2026.

• In Q1 2026, Capital Expenditures fell 22.7% year-over-year to $436.0 million; the TTM figure through Mar 2026 stood at $2.5 billion (down 35.82% YoY), while the FY2025 annual figure was $2.6 billion, down 9.63% from the prior year.
• Capital Expenditures slipped to $436.0 million in Q1 2026, from $845.0 million in the prior quarter.
• Over the last five years, Capital Expenditures for PFE reached as high as $2.2 billion in Q4 2022 and fell as low as $436.0 million in Q1 2026.
• The 5-year median for Capital Expenditures is $751.0 million (2022), against an average of $928.9 million.
• Annual changes were most pronounced in 2024 — Capital Expenditures soared 145.93% — and 2025, when it sank 69.78%.
• A 5-year view of Capital Expenditures shows it stood at $2.2 billion in 2022, then plunged by 53.29% to $1.0 billion in 2023, then surged by 90.8% to $2.0 billion in 2024, then sank by 57.58% to $845.0 million in 2025, then sank by 48.4% to $436.0 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $436.0 million, $845.0 million, and $602.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.